Clinical Trial 55289

Philadelphia, PA 19114


Summary:

You are being asked whether you would like to voluntarily participate in a research study to test a new drug called upadacitinib that is approved by the U.S. Food and Drug Administration (FDA) to treat rheumatoid arthritis (RA). Your medical history suggests you may be a good fit to help us learn how this study drug could help you and others with rheumatoid arthritis.   

The purpose of this study is to see if the study drug, upadacitinib 15 mg once a day tablet, is safe and is effective while taking methotrexate when compared to taking adalimumab 40 mg every other week (Humira®, approved drug for treatment of rheumatoid arthritis [RA]) while taking methotrexate, after having an inadequate response or intolerance to one drug class called tumor necrosis factor inhibitor (TNFi) used for the treatment of RA. 



Criteria:

Diagnosed with Rheumatoid Arthritis for at least 3 months 

Been treated with RA medication but still seeing symptoms 

Currently on methotrexate for at least 3 months 


Qualified Participants May Receive:

  • Study-related medication

  • Exams & lab work at no cost

  • If you qualify, you may be compensated for time and travel (up to $1,900)


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.